{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:59:54Z","timestamp":1793833194600,"version":"4.6.1"},"reference-count":193,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biol Eng"],"DOI":"10.1186\/s13036-025-00570-4","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T11:24:08Z","timestamp":1762255448000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Human preclinical multiple myeloma in vitro models for disease modeling and therapy screening"],"prefix":"10.1186","volume":"19","author":[{"given":"Mikayla","family":"Ybarra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaehun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Ya","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"issue":"2","key":"570_CR1","doi-asserted-by":"publisher","first-page":"103920","DOI":"10.1016\/j.sjbs.2023.103920","volume":"31","author":"MS Abduh","year":"2024","unstructured":"Abduh MS. An overview of multiple myeloma: a monoclonal plasma cell malignancy\u2019s diagnosis, management, and treatment modalities. Saudi J Biol Sci. 2024;31(2):103920.","journal-title":"Saudi J Biol Sci"},{"issue":"3","key":"570_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/ejh.13003","volume":"100","author":"D Ribatti","year":"2018","unstructured":"Ribatti D. A historical perspective on milestones in multiple myeloma research. Eur J Haematol. 2018;100(3):221\u201328.","journal-title":"Eur J Haematol"},{"issue":"325","key":"570_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.morpho.2015.02.001","volume":"99","author":"B Ribourtout","year":"2015","unstructured":"Ribourtout B, Zandecki M. Plasma cell morphology in multiple myeloma and related disorders. Morphologie. 2015;99(325):38\u201362.","journal-title":"Morphologie"},{"issue":"6","key":"570_CR4","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3816\/CLML.2010.n.080","volume":"10","author":"G Talamo","year":"2010","unstructured":"Talamo G, et al. Beyond the CRAB symptoms: a study of presenting clinical manifestations of multiple myeloma. Clin Lymphoma Myeloma Leuk. 2010;10(6):464\u201368.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"26","key":"570_CR5","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863\u201369.","journal-title":"J Clin Oncol"},{"issue":"12","key":"570_CR6","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538\u201348.","journal-title":"Lancet Oncol"},{"issue":"18","key":"570_CR7","first-page":"4546","volume":"59","author":"H Avet-Loiseau","year":"1999","unstructured":"Avet-Loiseau H, et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du My\u00e9lome. Cancer Res. 1999;59(18):4546\u201350.","journal-title":"Cancer Res"},{"issue":"2","key":"570_CR8","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/ajh.26785","volume":"98","author":"C Dumontet","year":"2023","unstructured":"Dumontet C, et al. Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: a multicenter Intergroupe Francophone du My\u00e9lome study. Am J Hematol. 2023;98(2):264\u201371.","journal-title":"Am J Hematol"},{"issue":"11","key":"570_CR9","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1038\/sj.leu.2403518","volume":"18","author":"H Kaufmann","year":"2004","unstructured":"Kaufmann H, et al. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma. Leukemia. 2004;18(11):1879\u201382.","journal-title":"Leukemia"},{"issue":"5","key":"570_CR10","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","volume":"108","author":"I Hanamura","year":"2006","unstructured":"Hanamura I, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood. 2006;108(5):1724\u201332.","journal-title":"Blood"},{"issue":"13","key":"570_CR11","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1182\/blood.2022016212","volume":"141","author":"N Stong","year":"2023","unstructured":"Stong N, et al. The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM. Blood. 2023;141(13):1574\u201383.","journal-title":"Blood"},{"issue":"1","key":"570_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41408-023-00933-4","volume":"13","author":"A Schavgoulidze","year":"2023","unstructured":"Schavgoulidze A, et al. Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions. Blood Cancer J. 2023;13(1):160.","journal-title":"Blood Cancer J"},{"issue":"7","key":"570_CR13","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.3324\/haematol.2009.016329","volume":"95","author":"FM Ross","year":"2010","unstructured":"Ross FM, et al. The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. Haematologica. 2010;95(7):1221\u201325.","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"570_CR14","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1182\/blood-2023-182845","volume":"142","author":"A Vaishnav","year":"2023","unstructured":"Vaishnav A, et al. Deletion 1p at time of diagnosis of multiple myeloma portends inferior outcomes. Blood. 2023;142(Supplement 1):1974\u20131974.","journal-title":"Blood"},{"issue":"7","key":"570_CR15","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.3324\/haematol.2009.016436","volume":"95","author":"K Neben","year":"2010","unstructured":"Neben K, et al. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica. 2010;95(7):1150\u201357.","journal-title":"Haematologica"},{"issue":"3","key":"570_CR16","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nrc746","volume":"2","author":"WM Kuehl","year":"2002","unstructured":"Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2(3):175\u201387.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"570_CR17","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1182\/blood.V100.4.1417.h81602001417_1417_1424","volume":"100","author":"R Fonseca","year":"2002","unstructured":"Fonseca R, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 2002;100(4):1417\u201324.","journal-title":"Blood"},{"issue":"11","key":"570_CR18","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","volume":"101","author":"R Fonseca","year":"2003","unstructured":"Fonseca R, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101(11):4569\u201375.","journal-title":"Blood"},{"issue":"3","key":"570_CR19","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1182\/blood.V97.3.822","volume":"97","author":"H Avet-Loiseau","year":"2001","unstructured":"Avet-Loiseau H, et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du My\u00e9lome and the Groupe Fran\u00e7ais de Cytog\u00e9n\u00e9tique H\u00e9matologique. Blood. 2001;97(3):822\u201325.","journal-title":"Blood"},{"issue":"11","key":"570_CR20","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/blood.V106.11.1552.1552","volume":"106","author":"I Hanamura","year":"2005","unstructured":"Hanamura I, et al. Identification of three novel chromosomal translocation partners involving the immunoglobulin loci in newly diagnosed myeloma and human myeloma cell lines. Blood. 2005;106(11):1552\u20131552.","journal-title":"Blood"},{"issue":"7339","key":"570_CR21","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature09837","volume":"471","author":"MA Chapman","year":"2011","unstructured":"Chapman MA, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471(7339):467\u201372.","journal-title":"Nature"},{"issue":"1","key":"570_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","volume":"25","author":"JG Lohr","year":"2014","unstructured":"Lohr JG, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25(1):91\u2013101.","journal-title":"Cancer Cell"},{"issue":"33","key":"570_CR23","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","volume":"33","author":"BA Walker","year":"2015","unstructured":"Walker BA, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol. 2015;33(33):3911\u201320.","journal-title":"J Clin Oncol"},{"issue":"1","key":"570_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/bjh.13256","volume":"169","author":"S Wei\u00dfbach","year":"2015","unstructured":"Wei\u00dfbach S, et al. The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma. Br J Haematol. 2015;169(1):57\u201370.","journal-title":"Br J Haematol"},{"issue":"5","key":"570_CR25","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2403407","volume":"391","author":"MA Dimopoulos","year":"2024","unstructured":"Dimopoulos MA, et al. Belantamab Mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med. 2024;391(5):408\u201321.","journal-title":"N Engl J Med"},{"key":"570_CR26","doi-asserted-by":"crossref","unstructured":"Richardson PG, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100(9):3063\u201367.","DOI":"10.1182\/blood-2002-03-0996"},{"issue":"2","key":"570_CR27","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1053\/sonc.2003.50078","volume":"30","author":"JB Zeldis","year":"2003","unstructured":"Zeldis JB, et al. Potential new therapeutics for Waldenstrom\u2019s macroglobulinemia. Semin Oncol. 2003;30(2):275\u201381.","journal-title":"Semin Oncol"},{"issue":"5","key":"570_CR28","doi-asserted-by":"publisher","first-page":"2052658","DOI":"10.1080\/21645515.2022.2052658","volume":"18","author":"A Gozzetti","year":"2022","unstructured":"Gozzetti A, et al. Anti CD38 monoclonal antibodies for multiple myeloma treatment. Hum Vaccin Immunother. 2022;18(5):2052658.","journal-title":"Hum Vaccin Immunother"},{"key":"570_CR29","doi-asserted-by":"crossref","unstructured":"Abramson HN. B-Cell Maturation Antigen (BCMA) as a target for new drug development in relapsed and\/or refractory multiple myeloma. Int J Mol Sci. 2020;21(15).","DOI":"10.3390\/ijms21155192"},{"key":"570_CR30","doi-asserted-by":"publisher","first-page":"991092","DOI":"10.3389\/fimmu.2022.991092","volume":"13","author":"E Chekol Abebe","year":"2022","unstructured":"Chekol Abebe E, et al. Ciltacabtagene autoleucel: the second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. Front Immunol. 2022;13:991092.","journal-title":"Front Immunol"},{"issue":"21","key":"570_CR31","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341(21):1565\u201371.","journal-title":"N Engl J Med"},{"issue":"21","key":"570_CR32","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa070596","volume":"357","author":"DM Weber","year":"2007","unstructured":"Weber DM, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357(21):2133\u201342.","journal-title":"N Engl J Med"},{"issue":"11","key":"570_CR33","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1182\/blood-2012-08-450742","volume":"121","author":"PG Richardson","year":"2013","unstructured":"Richardson PG, et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood. 2013;121(11):1961\u20137.","journal-title":"Blood"},{"issue":"17","key":"570_CR34","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","volume":"391","author":"T Facon","year":"2024","unstructured":"Facon T, et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391(17):1597\u2013609.","journal-title":"N Engl J Med"},{"issue":"8","key":"570_CR35","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.clml.2025.03.004","volume":"25","author":"A Perrot","year":"2025","unstructured":"Perrot A, et al. Survival, years of life lost and attrition rates in multiple myeloma patients in France. Clin Lymphoma Myeloma Leuk. 2025;25(8):606\u201314.e1.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"570_CR36","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1200\/JCO.22.00940","volume":"41","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, et al. Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial. J Clin Oncol. 2023;41(8):1590\u201399.","journal-title":"J Clin Oncol"},{"issue":"8","key":"570_CR37","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1200\/JCO.21.02734","volume":"41","author":"P Sonneveld","year":"2023","unstructured":"Sonneveld P, et al. Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label, phase III trial. J Clin Oncol. 2023;41(8):1600\u201309.","journal-title":"J Clin Oncol"},{"issue":"15","key":"570_CR38","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1002\/cncr.32978","volume":"126","author":"M Schinke","year":"2020","unstructured":"Schinke M, et al. Risk of disease recurrence and survival in patients with multiple myeloma: a German study group analysis using a conditional survival approach with long-term follow-up of 815 patients. Cancer. 2020;126(15):3504\u201315.","journal-title":"Cancer"},{"issue":"1","key":"570_CR39","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13045-021-01162-7","volume":"14","author":"CT Wallington-Beddoe","year":"2021","unstructured":"Wallington-Beddoe CT, Mynott RL. Prognostic and predictive biomarker developments in multiple myeloma. J Hematol Oncol. 2021;14(1):151.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"570_CR40","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1038\/s41375-020-0785-1","volume":"34","author":"V Sarin","year":"2020","unstructured":"Sarin V, et al. Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis. Leukemia. 2020;34(10):2754\u201365.","journal-title":"Leukemia"},{"issue":"11","key":"570_CR41","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1200\/JCO.23.01277","volume":"42","author":"F Maura","year":"2024","unstructured":"Maura F, et al. Genomic classification and individualized prognosis in multiple myeloma. J Clin Oncol. 2024;42(11):1229\u201340.","journal-title":"J Clin Oncol"},{"issue":"1","key":"570_CR42","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41746-024-01189-3","volume":"7","author":"Z Hussain","year":"2024","unstructured":"Hussain Z, et al. Joint AI-driven event prediction and longitudinal modeling in newly diagnosed and relapsed multiple myeloma. NPJ Digit Med. 2024;7(1):200.","journal-title":"NPJ Digit Med"},{"issue":"2","key":"570_CR43","doi-asserted-by":"publisher","first-page":"609","DOI":"10.4049\/jimmunol.122.2.609","volume":"122","author":"J Radl","year":"1979","unstructured":"Radl J, et al. Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL\/KaLwRij mice. J Immunol. 1979;122(2):609\u201313.","journal-title":"J Immunol"},{"issue":"12","key":"570_CR44","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1172\/JCI200420369","volume":"113","author":"WC Cheung","year":"2004","unstructured":"Cheung WC, et al. Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice. J Clin Invest. 2004;113(12):1763\u201373.","journal-title":"J Clin Invest"},{"issue":"1","key":"570_CR45","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/j.1365-2249.1992.tb05845.x","volume":"90","author":"LA Cavacini","year":"1992","unstructured":"Cavacini LA, et al. Human immunoglobulin production in immunodeficient mice: enhancement by immunosuppression of host and in vitro activation of human mononuclear cells. Clin Exp Immunol. 1992;90(1):135\u201340.","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"570_CR46","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/s41591-022-02178-3","volume":"29","author":"M Larrayoz","year":"2023","unstructured":"Larrayoz M, et al. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma. Nat Med. 2023;29(3):632\u201345.","journal-title":"Nat Med"},{"issue":"10","key":"570_CR47","doi-asserted-by":"publisher","first-page":"e2219439120","DOI":"10.1073\/pnas.2219439120","volume":"120","author":"W Winkler","year":"2023","unstructured":"Winkler W, et al. Mouse models of human multiple myeloma subgroups. Proc Natl Acad Sci. 2023;120(10):e2219439120.","journal-title":"Proc Natl Acad Sci"},{"key":"570_CR48","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/bonekey.2015.142","volume":"5","author":"ST Lwin","year":"2016","unstructured":"Lwin ST, Edwards CM, Silbermann R. Preclinical animal models of multiple myeloma. Bonekey Rep. 2016;5:772.","journal-title":"Bonekey Rep"},{"issue":"6","key":"570_CR49","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/bjc.1992.415","volume":"66","author":"LS Manning","year":"1992","unstructured":"Manning LS, et al. A model of multiple myeloma: culture of 5T33 murine myeloma cells and evaluation of tumorigenicity in the C57BL\/KaLwRij mouse. Br J Cancer. 1992;66(6):1088\u201393.","journal-title":"Br J Cancer"},{"issue":"3","key":"570_CR50","doi-asserted-by":"publisher","first-page":"e0119546","DOI":"10.1371\/journal.pone.0119546","volume":"10","author":"MA Lawson","year":"2015","unstructured":"Lawson MA, et al. NOD\/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease. PLoS One. 2015;10(3):e0119546.","journal-title":"PLoS One"},{"issue":"6","key":"570_CR51","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1111\/bjh.14493","volume":"176","author":"M Bar-Natan","year":"2017","unstructured":"Bar-Natan M, et al. Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1. Br J Haematol. 2017;176(6):929\u201338.","journal-title":"Br J Haematol"},{"issue":"4","key":"570_CR52","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s12032-025-02659-8","volume":"42","author":"Z Pooraskari","year":"2025","unstructured":"Pooraskari Z, et al. Evaluation of the antiangiogenic effect of AMG232 in multiple myeloma coculture systems. Med Oncol. 2025;42(4):107.","journal-title":"Med Oncol"},{"issue":"21","key":"570_CR53","doi-asserted-by":"publisher","first-page":"12888","DOI":"10.3390\/ijms232112888","volume":"23","author":"D Louren\u00e7o","year":"2022","unstructured":"Louren\u00e7o D, et al. Patient-derived multiple myeloma 3D models for personalized medicine-are we there yet? Int J Mol Sci. 2022;23(21):12888.","journal-title":"Int J Mol Sci"},{"key":"570_CR54","doi-asserted-by":"crossref","unstructured":"Wang L, et al. Complex in vitro model: a transformative model in drug development and precision medicine. Clin Transl Sci. 2023;17(2).","DOI":"10.1111\/cts.13695"},{"issue":"5","key":"570_CR55","doi-asserted-by":"publisher","first-page":"889","DOI":"10.3390\/cancers16050889","volume":"16","author":"SW Verbruggen","year":"2024","unstructured":"Verbruggen SW, Freeman CL, Freeman FE. Utilizing 3D models to unravel the dynamics of myeloma plasma cells\u2019 escape from the bone marrow microenvironment. Cancers. 2024;16(5):889.","journal-title":"Cancers"},{"issue":"3","key":"570_CR56","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/leu.2017.287","volume":"32","author":"AG Solimando","year":"2018","unstructured":"Solimando AG, et al. JAM-A as a prognostic factor and new therapeutic target in multiple myeloma. Leukemia. 2018;32(3):736\u201343.","journal-title":"Leukemia"},{"issue":"4","key":"570_CR57","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1182\/bloodadvances.2022007291","volume":"7","author":"J Kikuchi","year":"2023","unstructured":"Kikuchi J, et al. EMD originates from hyaluronan-induced homophilic interactions of CD44 variant-expressing MM cells under shear stress. Blood Adv. 2023;7(4):508\u201324.","journal-title":"Blood Adv"},{"key":"570_CR58","doi-asserted-by":"publisher","first-page":"106458","DOI":"10.1016\/j.compbiomed.2022.106458","volume":"153","author":"P Urdeitx","year":"2023","unstructured":"Urdeitx P, et al. Computational modeling of multiple myeloma interactions with resident bone marrow cells. Comput Biol Med. 2023;153:106458.","journal-title":"Comput Biol Med"},{"key":"570_CR59","first-page":"1","volume":"2","author":"PM Altrock","year":"2018","unstructured":"Altrock PM, et al. Computational model of progression to multiple myeloma identifies optimum screening strategies. JCO Clin Cancer Inf. 2018;2:1\u201312.","journal-title":"JCO Clin Cancer Inf"},{"issue":"10","key":"570_CR60","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1038\/s41375-021-01286-2","volume":"35","author":"A Mosquera Orgueira","year":"2021","unstructured":"Mosquera Orgueira A, et al. Survival prediction and treatment optimization of multiple myeloma patients using machine-learning models based on clinical and gene expression data. Leukemia. 2021;35(10):2924\u201335.","journal-title":"Leukemia"},{"key":"570_CR61","doi-asserted-by":"publisher","first-page":"102716","DOI":"10.1016\/j.ebiom.2020.102716","volume":"54","author":"P Sudalagunta","year":"2020","unstructured":"Sudalagunta P, et al. A pharmacodynamic model of clinical synergy in multiple myeloma. EBioMedicine. 2020;54:102716.","journal-title":"EBioMedicine"},{"key":"570_CR62","doi-asserted-by":"crossref","unstructured":"Yajima Y, et al. Facile fabrication processes for hydrogel-based microfluidic devices made of natural biopolymers. Biomicrofluidics. 2014;8(2).","DOI":"10.1063\/1.4871936"},{"issue":"21","key":"570_CR63","doi-asserted-by":"publisher","first-page":"7194","DOI":"10.1039\/D1BM00936B","volume":"9","author":"N Gorenkova","year":"2021","unstructured":"Gorenkova N, et al. The innate immune response of self-assembling silk fibroin hydrogels. Biomater Sci. 2021;9(21):7194\u2013204.","journal-title":"Biomater Sci"},{"issue":"3","key":"570_CR64","first-page":"1136","volume":"9","author":"MH Ma","year":"2003","unstructured":"Ma MH, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003;9(3):1136\u201344.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"570_CR65","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/cancers13010056","volume":"13","author":"AA Fitzgerald","year":"2021","unstructured":"Fitzgerald AA, Li E, Weiner LM. 3D culture systems for exploring cancer immunology. Cancers. 2021;13(1):56.","journal-title":"Cancers"},{"issue":"5","key":"570_CR66","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1182\/blood.V61.5.929.929","volume":"61","author":"BG Durie","year":"1983","unstructured":"Durie BG, Young LA, Salmon SE. Human myeloma in vitro colony growth: interrelationships between drug sensitivity, cell kinetics, and patient survival duration. Blood. 1983;61(5):929\u201334.","journal-title":"Blood"},{"issue":"21","key":"570_CR67","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1182\/blood.V124.21.2069.2069","volume":"124","author":"P De La Puente","year":"2014","unstructured":"De La Puente P, et al. 3D tissue-engineered bone marrow cultures induce drug resistance, de-differentiation and cytokine expression changes in multiple myeloma. Blood. 2014;124(21):2069\u20132069.","journal-title":"Blood"},{"issue":"6","key":"570_CR68","doi-asserted-by":"publisher","first-page":"e1434465","DOI":"10.1080\/2162402X.2018.1434465","volume":"7","author":"MVJ Braham","year":"2018","unstructured":"Braham MVJ, et al. Cellular immunotherapy on primary multiple myeloma expanded in a 3D bone marrow niche model. OncoImmunology. 2018;7(6):e1434465.","journal-title":"OncoImmunology"},{"issue":"4","key":"570_CR69","first-page":"910","volume":"14","author":"M Kapa\u0142czy\u0144ska","year":"2018","unstructured":"Kapa\u0142czy\u0144ska M, et al. 2D and 3D cell cultures - a comparison of different types of cancer cell cultures. Arch Med Sci. 2018;14(4):910\u201319.","journal-title":"Arch Med Sci"},{"issue":"1","key":"570_CR70","doi-asserted-by":"publisher","first-page":"18380","DOI":"10.1038\/s41598-023-45144-w","volume":"13","author":"ZN Abbas","year":"2023","unstructured":"Abbas ZN, et al. Comparative analysis between 2D and 3D colorectal cancer culture models for insights into cellular morphological and transcriptomic variations. Sci Rep. 2023;13(1):18380.","journal-title":"Sci Rep"},{"key":"570_CR71","doi-asserted-by":"crossref","unstructured":"Huang YH, et al. Constitutive activation of STAT3 in myeloma cells cultured in a three-dimensional, reconstructed bone marrow model. Cancers (Basel). 2018;10(6).","DOI":"10.3390\/cancers10060206"},{"issue":"4","key":"570_CR72","doi-asserted-by":"publisher","first-page":"293","DOI":"10.5045\/br.2017.52.4.293","volume":"52","author":"SH Jung","year":"2017","unstructured":"Jung SH, et al. STAT3 expression is associated with poor survival in non-elderly adult patients with newly diagnosed multiple myeloma. Blood Res. 2017;52(4):293\u201399.","journal-title":"Blood Res"},{"key":"570_CR73","doi-asserted-by":"crossref","unstructured":"Chong PSY, Chng WJ, de Mel S. STAT3: a promising therapeutic target in multiple myeloma. Cancers (Basel). 2019;11(5).","DOI":"10.3390\/cancers11050731"},{"key":"570_CR74","doi-asserted-by":"crossref","unstructured":"Alhallak K, et al. A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma. Sci Rep. 2021;11(1).","DOI":"10.1038\/s41598-021-98760-9"},{"key":"570_CR75","doi-asserted-by":"crossref","unstructured":"Mangani S, Kremmydas S, Karamanos NK. Mimicking the complexity of solid tumors: how spheroids could advance cancer preclinical transformative approaches. Cancers (Basel). 2025;17(7).","DOI":"10.3390\/cancers17071161"},{"issue":"1","key":"570_CR76","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12929-024-00994-y","volume":"31","author":"WH Abuwatfa","year":"2024","unstructured":"Abuwatfa WH, Pitt WG, Husseini GA. Scaffold-based 3D cell culture models in cancer research. J Biomed Sci. 2024;31(1):7.","journal-title":"J Biomed Sci"},{"key":"570_CR77","doi-asserted-by":"crossref","unstructured":"Ryu NE, Lee SH, Park H. Spheroid culture system methods and applications for mesenchymal stem cells. Cells. 2019;8(12).","DOI":"10.3390\/cells8121620"},{"issue":"10","key":"570_CR78","doi-asserted-by":"publisher","first-page":"e2102337","DOI":"10.1002\/adhm.202102337","volume":"11","author":"T Gonzalez-Fernandez","year":"2022","unstructured":"Gonzalez-Fernandez T, et al. Engineered cell-secreted extracellular matrix modulates cell spheroid mechanosensing and amplifies their response to inductive cues for the formation of mineralized tissues. Adv Healthc Mater. 2022;11(10):e2102337.","journal-title":"Adv Healthc Mater"},{"issue":"7","key":"570_CR79","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1182\/blood-2008-02-142430","volume":"112","author":"J Kirshner","year":"2008","unstructured":"Kirshner J, et al. A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. Blood. 2008;112(7):2935\u201345.","journal-title":"Blood"},{"issue":"5","key":"570_CR80","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s00432-021-03854-6","volume":"148","author":"JM Waldschmidt","year":"2022","unstructured":"Waldschmidt JM, et al. Ex vivo propagation in a novel 3D high-throughput co-culture system for multiple myeloma. J Cancer Res Clin Oncol. 2022;148(5):1045\u201355.","journal-title":"J Cancer Res Clin Oncol"},{"key":"570_CR81","first-page":"321","volume":"14","author":"S Luanpitpong","year":"2025","unstructured":"Luanpitpong S, et al. A high-throughput, three-dimensional multiple myeloma model recapitulating tumor-stroma interactions for CAR-Immune cell-mediated cytotoxicity assay. Immunotargets Ther. 2025;14:321\u201338.","journal-title":"Immunotargets Ther"},{"issue":"2","key":"570_CR82","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1158\/2159-8290.CD-22-0199","volume":"13","author":"AO Khan","year":"2023","unstructured":"Khan AO, et al. Human bone marrow organoids for disease modeling, discovery, and validation of therapeutic targets in hematologic malignancies. Cancer Discov. 2023;13(2):364\u201385.","journal-title":"Cancer Discov"},{"issue":"4","key":"570_CR83","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.immuni.2006.08.020","volume":"25","author":"X Shi","year":"2006","unstructured":"Shi X, et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity. 2006;25(4):595\u2013606.","journal-title":"Immunity"},{"issue":"42","key":"570_CR84","doi-asserted-by":"publisher","first-page":"68303","DOI":"10.18632\/oncotarget.11945","volume":"7","author":"Z Liu","year":"2016","unstructured":"Liu Z, et al. CD74 interacts with CD44 and enhances tumorigenesis and metastasis via RHOA-mediated cofilin phosphorylation in human breast cancer cells. Oncotarget. 2016;7(42):68303\u201313.","journal-title":"Oncotarget"},{"key":"570_CR85","doi-asserted-by":"publisher","first-page":"609948","DOI":"10.3389\/fimmu.2020.609948","volume":"11","author":"JT Noe","year":"2020","unstructured":"Noe JT, Mitchell RA. MIF-Dependent control of tumor immunity. Front Immunol. 2020;11:609948.","journal-title":"Front Immunol"},{"key":"570_CR86","doi-asserted-by":"crossref","unstructured":"Shen Y, et al. comBO: a combined human bone and lympho-myeloid bone marrow organoid for pre-clinical modelling of haematopoietic disorders. bioRxiv. 2025;2025.02.16.638505.","DOI":"10.1101\/2025.02.16.638505"},{"issue":"1","key":"570_CR87","doi-asserted-by":"publisher","first-page":"15663","DOI":"10.1038\/s41598-019-52204-7","volume":"9","author":"P W\u00f6rsd\u00f6rfer","year":"2019","unstructured":"W\u00f6rsd\u00f6rfer P, et al. Generation of complex human organoid models including vascular networks by incorporation of mesodermal progenitor cells. Sci Rep. 2019;9(1):15663.","journal-title":"Sci Rep"},{"issue":"1","key":"570_CR88","doi-asserted-by":"publisher","first-page":"19550","DOI":"10.1038\/s41598-021-98911-y","volume":"11","author":"AS Tatla","year":"2021","unstructured":"Tatla AS, et al. A vascularized tumoroid model for human glioblastoma angiogenesis. Sci Rep. 2021;11(1):19550.","journal-title":"Sci Rep"},{"issue":"1","key":"570_CR89","doi-asserted-by":"publisher","first-page":"21966","DOI":"10.1038\/s41598-021-01513-x","volume":"11","author":"R Rimal","year":"2021","unstructured":"Rimal R, et al. 3-D vascularized breast cancer model to study the role of osteoblast in formation of a pre-metastatic niche. Sci Rep. 2021;11(1):21966.","journal-title":"Sci Rep"},{"key":"570_CR90","doi-asserted-by":"publisher","first-page":"1484738","DOI":"10.3389\/fbioe.2025.1484738","volume":"13","author":"F Maggiotto","year":"2025","unstructured":"Maggiotto F, et al. 3D bioprinting for the production of a perfusable vascularized model of a cancer niche. Front Bioeng Biotechnol. 2025;13:1484738.","journal-title":"Front Bioeng Biotechnol"},{"issue":"8a","key":"570_CR91","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1111\/j.1582-4934.2009.00853.x","volume":"13","author":"DW Hutmacher","year":"2009","unstructured":"Hutmacher DW, et al. Translating tissue engineering technology platforms into cancer research. J Cell Mol Med. 2009;13(8a):1417\u201327.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"570_CR92","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13045-019-0714-9","volume":"12","author":"M Cuc\u00e8","year":"2019","unstructured":"Cuc\u00e8 M, et al. Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. J Hematol Oncol. 2019;12(1):32.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"570_CR93","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41556-019-0439-6","volume":"22","author":"C Baccin","year":"2020","unstructured":"Baccin C, et al. Combined single-cell and spatial transcriptomics reveal the molecular, cellular and spatial bone marrow niche organization. Nat Cell Biol. 2020;22(1):38\u201348.","journal-title":"Nat Cell Biol"},{"issue":"7","key":"570_CR94","doi-asserted-by":"publisher","first-page":"990","DOI":"10.3390\/biology12070990","volume":"12","author":"J-P Capp","year":"2023","unstructured":"Capp J-P, Bataille R. The ins and outs of endosteal niche disruption in the bone marrow: relevance for myeloma oncogenesis. Biology. 2023;12(7):990.","journal-title":"Biology"},{"key":"570_CR95","doi-asserted-by":"publisher","first-page":"8983","DOI":"10.1038\/ncomms9983","volume":"6","author":"MA Lawson","year":"2015","unstructured":"Lawson MA, et al. Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nat Commun. 2015;6:8983.","journal-title":"Nat Commun"},{"key":"570_CR96","doi-asserted-by":"publisher","first-page":"4280407","DOI":"10.1155\/2016\/4280407","volume":"2016","author":"G Sun","year":"2016","unstructured":"Sun G, et al. The three-dimensional culture system with Matrigel and neurotrophic factors preserves the structure and function of spiral ganglion neuron in vitro. Neural Plast. 2016;2016:4280407.","journal-title":"Neural Plast"},{"issue":"1","key":"570_CR97","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s42003-021-02691-0","volume":"4","author":"A Alave Reyes-Furrer","year":"2021","unstructured":"Alave Reyes-Furrer A, et al. Matrigel 3D bioprinting of contractile human skeletal muscle models recapitulating exercise and pharmacological responses. Commun Biol. 2021;4(1):1183.","journal-title":"Commun Biol"},{"key":"570_CR98","doi-asserted-by":"publisher","first-page":"1362696","DOI":"10.3389\/fcell.2024.1362696","volume":"12","author":"S Tahara","year":"2024","unstructured":"Tahara S, et al. Comparison of three-dimensional cell culture techniques of dedifferentiated liposarcoma and their integration with future research. Front Cell Dev Biol. 2024;12:1362696.","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"570_CR99","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1177\/2472555219834698","volume":"24","author":"MA Badea","year":"2019","unstructured":"Badea MA, et al. Influence of matrigel on single- and multiple-spheroid cultures in breast cancer research. SLAS Discov. 2019;24(5):563\u201378.","journal-title":"SLAS Discov"},{"issue":"1","key":"570_CR100","doi-asserted-by":"publisher","first-page":"9578","DOI":"10.1038\/s41598-025-93700-3","volume":"15","author":"C Dondi","year":"2025","unstructured":"Dondi C, et al. Multiparametric physicochemical analysis of a type 1 collagen 3D cell culture model using light and electron microscopy and mass spectrometry imaging. Sci Rep. 2025;15(1):9578.","journal-title":"Sci Rep"},{"issue":"1","key":"570_CR101","doi-asserted-by":"publisher","first-page":"16270","DOI":"10.1038\/s41598-018-33455-2","volume":"8","author":"Z Yuan","year":"2018","unstructured":"Yuan Z, et al. Development of a 3D collagen model for the in vitro evaluation of magnetic-assisted osteogenesis. Sci Rep. 2018;8(1):16270.","journal-title":"Sci Rep"},{"issue":"1","key":"570_CR102","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13045-024-01636-4","volume":"17","author":"D Hose","year":"2024","unstructured":"Hose D, et al. Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma. J Hematol Oncol. 2024;17(1):128.","journal-title":"J Hematol Oncol"},{"issue":"46","key":"570_CR103","doi-asserted-by":"publisher","first-page":"e1904580","DOI":"10.1002\/adma.201904580","volume":"31","author":"S Jordahl","year":"2019","unstructured":"Jordahl S, et al. Engineered fibrillar fibronectin networks as three-dimensional tissue scaffolds. Adv Mater. 2019;31(46):e1904580.","journal-title":"Adv Mater"},{"issue":"1","key":"570_CR104","doi-asserted-by":"publisher","first-page":"19950","DOI":"10.1038\/s41598-019-56276-3","volume":"9","author":"HJ Park","year":"2019","unstructured":"Park HJ, Helfman DM. Up-regulated fibronectin in 3D culture facilitates spreading of triple negative breast cancer cells on 2D through integrin \u03b2-5 and Src. Sci Rep. 2019;9(1):19950.","journal-title":"Sci Rep"},{"key":"570_CR105","doi-asserted-by":"crossref","unstructured":"Teworte S, et al. A fibronectin (FN)-silk 3D cell culture model as a screening tool for repurposed antifibrotic drug candidates for endometriosis. bioRxiv. 2024;2024.10.05.616776.","DOI":"10.1101\/2024.10.05.616776"},{"issue":"1","key":"570_CR106","doi-asserted-by":"publisher","first-page":"21273","DOI":"10.1038\/s41598-020-78087-7","volume":"10","author":"I Yakavets","year":"2020","unstructured":"Yakavets I, et al. Advanced co-culture 3D breast cancer model for investigation of fibrosis induced by external stimuli: optimization study. Sci Rep. 2020;10(1):21273.","journal-title":"Sci Rep"},{"key":"570_CR107","doi-asserted-by":"crossref","unstructured":"Xiao W, et al. Hyaluronic-acid based hydrogels for 3-dimensional culture of patient-derived glioblastoma cells. J Vis Exp. 2018;138.","DOI":"10.3791\/58176-v"},{"issue":"1","key":"570_CR108","doi-asserted-by":"publisher","first-page":"19560","DOI":"10.1038\/s41598-024-69047-6","volume":"14","author":"G Demirel","year":"2024","unstructured":"Demirel G, et al. The use of hyaluronic acid in a 3D biomimetic scaffold supports spheroid formation and the culture of cancer stem cells. Sci Rep. 2024;14(1):19560.","journal-title":"Sci Rep"},{"issue":"6","key":"570_CR109","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1021\/bm500318d","volume":"15","author":"AF Jeffery","year":"2014","unstructured":"Jeffery AF, et al. Hyaluronic acid-based 3D culture model for in vitro testing of electrode biocompatibility. Biomacromolecules. 2014;15(6):2157\u201365.","journal-title":"Biomacromolecules"},{"issue":"1","key":"570_CR110","doi-asserted-by":"publisher","first-page":"4436","DOI":"10.1038\/s41598-024-54912-1","volume":"14","author":"A Pangjantuk","year":"2024","unstructured":"Pangjantuk A, et al. 3D culture of alginate-hyaluronic acid hydrogel supports the stemness of human mesenchymal stem cells. Sci Rep. 2024;14(1):4436.","journal-title":"Sci Rep"},{"key":"570_CR111","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3389\/fphys.2018.00679","volume":"9","author":"BM R\u00fcger","year":"2018","unstructured":"R\u00fcger BM, et al. Vascular morphogenesis in the context of inflammation: self-organization in a fibrin-based 3D culture system. Front Physiol. 2018;9:679.","journal-title":"Front Physiol"},{"issue":"14","key":"570_CR112","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1091\/mbc.E20-01-0079","volume":"31","author":"S Natan","year":"2020","unstructured":"Natan S, et al. Long-range mechanical coupling of cells in 3D fibrin gels. Mol Biol Cell. 2020;31(14):1474\u201385.","journal-title":"Mol Biol Cell"},{"issue":"3","key":"570_CR113","first-page":"229","volume":"6","author":"EG Ayg\u00fcn","year":"2022","unstructured":"Ayg\u00fcn EG, et al. Effects of fibrin matrix and Ishikawa cells on in vitro 3D uterine tissue cultures on a rat model: a controlled study. J Educ Chang Surg Med. 2022;6(3):229\u201342.","journal-title":"J Educ Chang Surg Med"},{"issue":"1","key":"570_CR114","doi-asserted-by":"publisher","first-page":"17727","DOI":"10.1038\/s41598-021-97059-z","volume":"11","author":"N Shah","year":"2021","unstructured":"Shah N, et al. Gelatin methacrylate hydrogels culture model for glioblastoma cells enriches for mesenchymal-like state and models interactions with immune cells. Sci Rep. 2021;11(1):17727.","journal-title":"Sci Rep"},{"key":"570_CR115","doi-asserted-by":"crossref","unstructured":"Hipwood L, et al. Semi-synthetic click-gelatin hydrogels as tunable platforms for 3D cancer cell culture. Gels. 2022;8(12).","DOI":"10.3390\/gels8120821"},{"issue":"10","key":"570_CR116","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.21037\/tlcr-24-490","volume":"13","author":"Z Zhao","year":"2024","unstructured":"Zhao Z, et al. Construction of a lung cancer 3D culture model based on alginate\/gelatin micro-beads for drug evaluation. Transl Lung Cancer Res. 2024;13(10):2698\u2013712.","journal-title":"Transl Lung Cancer Res"},{"key":"570_CR117","doi-asserted-by":"publisher","first-page":"1200618","DOI":"10.3389\/fbioe.2023.1200618","volume":"11","author":"S Tahri","year":"2023","unstructured":"Tahri S, et al. Human epidermal keratinocytes and human dermal fibroblasts interactions seeded on gelatin hydrogel for future application in skin in vitro 3-dimensional model. Front Bioeng Biotechnol. 2023;11:1200618.","journal-title":"Front Bioeng Biotechnol"},{"key":"570_CR118","doi-asserted-by":"crossref","unstructured":"Parikh MR, et al. A three-dimensional tissue culture model to study primary human bone marrow and its malignancies. J Vis Exp. 2014;85.","DOI":"10.3791\/50947-v"},{"issue":"1","key":"570_CR119","doi-asserted-by":"publisher","first-page":"22668","DOI":"10.1038\/s41598-021-01036-5","volume":"11","author":"A Gandin","year":"2021","unstructured":"Gandin A, et al. Simple yet effective methods to probe hydrogel stiffness for mechanobiology. Sci Rep. 2021;11(1):22668.","journal-title":"Sci Rep"},{"issue":"1","key":"570_CR120","first-page":"67","volume":"28","author":"NK Narayanan","year":"2014","unstructured":"Narayanan NK, et al. Characterization of multiple myeloma clonal cell expansion and stromal Wnt\/\u03b2-catenin signaling in hyaluronic acid-based 3D hydrogel. In Vivo. 2014;28(1):67\u201373.","journal-title":"In Vivo"},{"issue":"2","key":"570_CR121","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1182\/blood.2019004537","volume":"136","author":"C Perez","year":"2020","unstructured":"Perez C, et al. Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma. Blood. 2020;136(2):199\u2013209.","journal-title":"Blood"},{"key":"570_CR122","doi-asserted-by":"crossref","unstructured":"Martini S, et al. Long-termin vitromaintenance of plasma cells in a hydrogel-enclosed human bone marrow microphysiological 3D model system. Biofabrication. 2024;16(4).","DOI":"10.1088\/1758-5090\/ad5dfe"},{"issue":"47","key":"570_CR123","doi-asserted-by":"publisher","first-page":"77326","DOI":"10.18632\/oncotarget.12643","volume":"7","author":"J Jakubikova","year":"2016","unstructured":"Jakubikova J, et al. A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications. Oncotarget. 2016;7(47):77326\u201341.","journal-title":"Oncotarget"},{"issue":"22","key":"570_CR124","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1182\/blood-2014-02-558007","volume":"124","author":"MR Reagan","year":"2014","unstructured":"Reagan MR, et al. Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. Blood. 2014;124(22):3250\u201359.","journal-title":"Blood"},{"key":"570_CR125","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.bone.2018.01.023","volume":"118","author":"H Fairfield","year":"2019","unstructured":"Fairfield H, et al. Development of a 3D bone marrow adipose tissue model. Bone. 2019;118:77\u201388.","journal-title":"Bone"},{"key":"570_CR126","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.biomaterials.2015.09.017","volume":"73","author":"P de la Puente","year":"2015","unstructured":"de la Puente P, et al. 3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma. Biomaterials. 2015;73:70\u201384.","journal-title":"Biomaterials"},{"issue":"4","key":"570_CR127","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.biotechadv.2015.12.011","volume":"34","author":"C Mandrycky","year":"2016","unstructured":"Mandrycky C, et al. 3D bioprinting for engineering complex tissues. Biotechnol Adv. 2016;34(4):422\u201334.","journal-title":"Biotechnol Adv"},{"key":"570_CR128","doi-asserted-by":"crossref","unstructured":"Saini G, et al. Applications of 3D bioprinting in tissue engineering and regenerative medicine. J Clin Med. 2021;10(21).","DOI":"10.3390\/jcm10214966"},{"issue":"2","key":"570_CR129","first-page":"147","volume":"40","author":"MA Ortega","year":"2025","unstructured":"Ortega MA, et al. Advances in 3D bioprinting to enhance translational applications in bone tissue engineering and regenerative medicine. Histol Histopathol. 2025;40(2):147\u201356.","journal-title":"Histol Histopathol"},{"key":"570_CR130","doi-asserted-by":"crossref","unstructured":"Tolmacheva N, Bhattacharyya A, Noh I. Calcium phosphate biomaterials for 3D bioprinting in bone tissue engineering. Biomimetics (Basel). 2024;9(2).","DOI":"10.3390\/biomimetics9020095"},{"issue":"5","key":"570_CR131","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1089\/ten.tec.2017.0467","volume":"24","author":"MVJ Braham","year":"2018","unstructured":"Braham MVJ, et al. Endosteal and perivascular subniches in a 3D bone marrow model for multiple myeloma. Tissue Eng Part C Methods. 2018;24(5):300\u201312.","journal-title":"Tissue Eng Part C Methods"},{"issue":"5","key":"570_CR132","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.cellsig.2004.10.004","volume":"17","author":"S C\u00f4t\u00e9","year":"2005","unstructured":"C\u00f4t\u00e9 S, Lemieux R, Simard C. The survival of IL-6-dependent myeloma cells critically relies on their capability to transit the G1 to S phase interval of the cell cycle. Cell Signal. 2005;17(5):615\u201324.","journal-title":"Cell Signal"},{"issue":"1","key":"570_CR133","doi-asserted-by":"publisher","first-page":"17319","DOI":"10.1038\/s41598-020-74352-x","volume":"10","author":"PL Mulcrone","year":"2020","unstructured":"Mulcrone PL, et al. Osteocyte Vegf-a contributes to myeloma-associated angiogenesis and is regulated by Fgf23. Sci Rep. 2020;10(1):17319.","journal-title":"Sci Rep"},{"key":"570_CR134","doi-asserted-by":"crossref","unstructured":"Ito S, Sato T, Maeta T. Role and therapeutic targeting of SDF-1\u03b1\/CXCR4 axis in multiple myeloma. Cancers (Basel). 2021;13(8).","DOI":"10.3390\/cancers13081793"},{"issue":"8","key":"570_CR135","first-page":"2606","volume":"109","author":"HM Sabol","year":"2024","unstructured":"Sabol HM, et al. A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma. Haematologica. 2024;109(8):2606\u201318.","journal-title":"Haematologica"},{"issue":"10","key":"570_CR136","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/j.clml.2019.09.045","volume":"19","author":"C Rodriguez","year":"2019","unstructured":"Rodriguez C, et al. High throughput 3D bioprinting of patient-derived multiple myeloma organoid models for niche recapitulation and chemosensitivity assessment. Clin Lymphoma Myeloma Leuk. 2019;19(10):e30\u201331.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"570_CR137","doi-asserted-by":"publisher","first-page":"2100884","DOI":"10.1002\/adhm.202100884","volume":"11","author":"D Wu","year":"2022","unstructured":"Wu D, et al. A 3D-Bioprinted multiple myeloma model. Adv Healthcare Mater. 2022;11(7):2100884.","journal-title":"Adv Healthcare Mater"},{"issue":"1","key":"570_CR138","doi-asserted-by":"publisher","first-page":"10134","DOI":"10.1038\/s41598-025-94093-z","volume":"15","author":"BH Jun","year":"2025","unstructured":", Jun BH, et al. Fabrication of a novel 3D-printed perfusion bioreactor for complex cell culture models. Sci Rep. 2025;15(1):10134.","journal-title":"Sci Rep"},{"issue":"2","key":"570_CR139","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/0014-4827(88)90275-3","volume":"179","author":"RJ Klebe","year":"1988","unstructured":"Klebe RJ. Cytoscribing: a method for micropositioning cells and the construction of two- and three-dimensional synthetic tissues. Exp Cell Res. 1988;179(2):362\u201373.","journal-title":"Exp Cell Res"},{"issue":"39","key":"570_CR140","doi-asserted-by":"publisher","first-page":"e2302101120","DOI":"10.1073\/pnas.2302101120","volume":"120","author":"KH Griffin","year":"2023","unstructured":"Griffin KH, et al. Engineered bone marrow as a clinically relevant ex vivo model for primary bone cancer research and drug screening. Proc Natl Acad Sci. 2023;120(39):e2302101120.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"570_CR141","doi-asserted-by":"publisher","first-page":"101601","DOI":"10.1016\/j.xpro.2022.101601","volume":"3","author":"D Belloni","year":"2022","unstructured":"Belloni D, et al. Protocol for generation of 3D bone marrow surrogate microenvironments in a rotary cell culture system. Star Protoc. 2022;3(3):101601.","journal-title":"Star Protoc"},{"issue":"8","key":"570_CR142","doi-asserted-by":"publisher","first-page":"e71613","DOI":"10.1371\/journal.pone.0071613","volume":"8","author":"M Ferrarini","year":"2013","unstructured":"Ferrarini M, et al. Ex-vivo dynamic 3-D culture of human tissues in the RCCS\u2122 bioreactor allows the study of Multiple Myeloma biology and response to therapy. PLoS One. 2013;8(8):e71613.","journal-title":"PLoS One"},{"key":"570_CR143","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/978-1-4939-7021-6_13","volume":"1612","author":"M Ferrarini","year":"2017","unstructured":"Ferrarini M, et al. 3D-Dynamic culture models of multiple myeloma. Methods Mol Biol. 2017;1612:177\u201390.","journal-title":"Methods Mol Biol"},{"issue":"4","key":"570_CR144","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3324\/haematol.2017.167486","volume":"103","author":"D Belloni","year":"2018","unstructured":"Belloni D, et al. Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment. Haematologica. 2018;103(4):707\u201316.","journal-title":"Haematologica"},{"issue":"1","key":"570_CR145","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41413-022-00190-4","volume":"10","author":"L Wang","year":"2022","unstructured":"Wang L, et al. Mechanical regulation of bone remodeling. Bone Res. 2022;10(1):16.","journal-title":"Bone Res"},{"key":"570_CR146","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3389\/fbioe.2016.00087","volume":"4","author":"C Wittkowske","year":"2016","unstructured":"Wittkowske C, et al. In vitro bone cell models: impact of fluid shear stress on bone formation. Front Bioeng Biotechnol. 2016;4:87.","journal-title":"Front Bioeng Biotechnol"},{"key":"570_CR147","doi-asserted-by":"crossref","unstructured":"Koyilot MC, et al. Breakthroughs and applications of organ-on-a-chip technology. Cells. 2022;11(11).","DOI":"10.3390\/cells11111828"},{"issue":"1","key":"570_CR148","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s43586-022-00118-6","volume":"2","author":"CM Leung","year":"2022","unstructured":"Leung CM, et al. A guide to the organ-on-a-chip. Nat Rev Methods Primers. 2022;2(1):33.","journal-title":"Nat Rev Methods Primers"},{"issue":"8","key":"570_CR149","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/s41576-022-00466-9","volume":"23","author":"DE Ingber","year":"2022","unstructured":"Ingber DE. Human organs-on-chips for disease modelling, drug development and personalized medicine. Nat Rev Genet. 2022;23(8):467\u201391.","journal-title":"Nat Rev Genet"},{"key":"570_CR150","doi-asserted-by":"crossref","unstructured":"Cao UMN, et al. Microfluidic organ-on-a-chip: a guide to biomaterial choice and fabrication. Int J Mol Sci. 2023;24(4).","DOI":"10.3390\/ijms24043232"},{"key":"570_CR151","doi-asserted-by":"crossref","unstructured":"An L, Liu Y, Liu Y. Organ-on-a-chip applications in microfluidic platforms. Micromachines (Basel). 2025;16(2).","DOI":"10.3390\/mi16020201"},{"issue":"2","key":"570_CR152","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.tips.2020.11.009","volume":"42","author":"C Ma","year":"2021","unstructured":"Ma C, et al. Organ-on-a-chip: a new paradigm for drug development. Trends Pharmacol Sci. 2021;42(2):119\u201333.","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"570_CR153","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s42003-021-01695-0","volume":"4","author":"P Zamprogno","year":"2021","unstructured":"Zamprogno P, et al. Second-generation lung-on-a-chip with an array of stretchable alveoli made with a biological membrane. Commun Biol. 2021;4(1):168.","journal-title":"Commun Biol"},{"issue":"5986","key":"570_CR154","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1126\/science.1188302","volume":"328","author":"D Huh","year":"2010","unstructured":"Huh D, et al. Reconstituting organ-level lung functions on a chip. Science. 2010;328(5986):1662\u201368.","journal-title":"Science"},{"issue":"8","key":"570_CR155","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1089\/ten.tec.2013.0490","volume":"20","author":"W Zhang","year":"2014","unstructured":"Zhang W, et al. Patient-specific 3D microfluidic tissue model for multiple myeloma. Tissue Eng Part C Methods. 2014;20(8):663\u201370.","journal-title":"Tissue Eng Part C Methods"},{"issue":"1","key":"570_CR156","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/s41598-022-05520-4","volume":"12","author":"C Sui","year":"2022","unstructured":"Sui C, Zilberberg J, Lee W. Microfluidic device engineered to study the trafficking of multiple myeloma cancer cells through the sinusoidal niche of bone marrow. Sci Rep. 2022;12(1):1439.","journal-title":"Sci Rep"},{"issue":"1","key":"570_CR157","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1158\/0008-5472.CAN-13-2397","volume":"74","author":"ZP Khin","year":"2014","unstructured":"Khin ZP, et al. A preclinical assay for chemosensitivity in multiple myeloma. Cancer Res. 2014;74(1):56\u201367.","journal-title":"Cancer Res"},{"key":"570_CR158","doi-asserted-by":"crossref","unstructured":"Ghoshal D, et al. Multi-Niche human bone marrow on-a-chip for studying the interactions of adoptive CAR-T cell therapies with multiple myeloma. bioRxiv. 2024;2024.04.08.588601.","DOI":"10.1101\/2024.04.08.588601"},{"issue":"44","key":"570_CR159","doi-asserted-by":"publisher","first-page":"eaba 5536","DOI":"10.1126\/sciadv.aba5536","volume":"6","author":"C Ma","year":"2020","unstructured":"Ma C, et al. Leukemia-on-a-chip: dissecting the chemoresistance mechanisms in B cell acute lymphoblastic leukemia bone marrow niche. Sci Adv. 2020;6(44):eaba5536.","journal-title":"Sci Adv"},{"key":"570_CR160","unstructured":"Ma C, et al. A bioengineered immunocompetent human leukemia chip for preclinical screening of CAR T cell immunotherapy. Res Sq. 2023."},{"key":"570_CR161","doi-asserted-by":"publisher","first-page":"640954","DOI":"10.3389\/fgene.2021.640954","volume":"12","author":"SH Mehdi","year":"2021","unstructured":"Mehdi SH, et al. Animal models of multiple myeloma bone disease. Front Genet. 2021;12:640954.","journal-title":"Front Genet"},{"issue":"1","key":"570_CR162","doi-asserted-by":"publisher","first-page":"5335","DOI":"10.1038\/s41467-023-40966-8","volume":"14","author":"DG Coffey","year":"2023","unstructured":"Coffey DG, et al. Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma. Nat Commun. 2023;14(1):5335.","journal-title":"Nat Commun"},{"issue":"12","key":"570_CR163","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1158\/1078-0432.CCR-14-1813","volume":"21","author":"IS Nijhof","year":"2015","unstructured":"Nijhof IS, et al. Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib. Clin Cancer Res. 2015;21(12):2802\u201310.","journal-title":"Clin Cancer Res"},{"key":"570_CR164","doi-asserted-by":"publisher","first-page":"100040","DOI":"10.1016\/j.mtbio.2019.100040","volume":"5","author":"R Spelat","year":"2020","unstructured":"Spelat R, et al. A worm gel-based 3D model to elucidate the paracrine interaction between multiple myeloma and mesenchymal stem cells. Mater Today Bio. 2020;5:100040.","journal-title":"Mater Today Bio"},{"key":"570_CR165","doi-asserted-by":"crossref","unstructured":"van Diest E, et al. Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds. J Immunother Cancer. 2021;9(11).","DOI":"10.1136\/jitc-2021-003850"},{"issue":"42","key":"570_CR166","doi-asserted-by":"publisher","first-page":"e2405257121","DOI":"10.1073\/pnas.2405257121","volume":"121","author":"I Baldassarri","year":"2024","unstructured":"Baldassarri I, et al. An engineered model of metastatic colonization of human bone marrow reveals breast cancer cell remodeling of the hematopoietic niche. Proc Natl Acad Sci U S A. 2024;121(42):e2405257121.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"570_CR167","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s40610-017-0055-9","volume":"3","author":"M Gal\u00e1n-D\u00edez","year":"2017","unstructured":"Gal\u00e1n-D\u00edez M, Kousteni S. The osteoblastic niche in hematopoiesis and hematological myeloid malignancies. Curr Mol Biol Rep. 2017;3(2):53\u201362.","journal-title":"Curr Mol Biol Rep"},{"issue":"2","key":"570_CR168","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/term.2507","volume":"12","author":"S Sieber","year":"2018","unstructured":"Sieber S, et al. Bone marrow-on-a-chip: long-term culture of human haematopoietic stem cells in a three-dimensional microfluidic environment. J Tissue Eng Regen Med. 2018;12(2):479\u201389.","journal-title":"J Tissue Eng Regen Med"},{"issue":"6","key":"570_CR169","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1021\/mp200279p","volume":"8","author":"AS Silva","year":"2011","unstructured":"Silva AS, Gatenby RA. Adaptation to survival in germinal center is the initial step in onset of indolent stage of multiple myeloma. Mol Pharm. 2011;8(6):2012\u201320.","journal-title":"Mol Pharm"},{"issue":"1","key":"570_CR170","doi-asserted-by":"publisher","first-page":"105741","DOI":"10.1016\/j.isci.2022.105741","volume":"26","author":"MVJ Braham","year":"2023","unstructured":"Braham MVJ, et al. A synthetic human 3D in vitro lymphoid model enhancing B-cell survival and functional differentiation. iScience. 2023;26(1):105741.","journal-title":"iScience"},{"issue":"2","key":"570_CR171","doi-asserted-by":"publisher","first-page":"e202451460","DOI":"10.1002\/eji.202451460","volume":"55","author":"E Fleischmann","year":"2025","unstructured":"Fleischmann E, Middelkamp V, van den Broek T. Deciphering the human germinal center: a review of models to study T-B cell interactions. Eur J Immunol. 2025;55(2):e202451460.","journal-title":"Eur. J. Immunol"},{"issue":"4","key":"570_CR172","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1021\/acscentsci.2c01473","volume":"9","author":"TD Moeller","year":"2023","unstructured":"Moeller TD, et al. Profiling germinal center-like B cell responses to conjugate vaccines using synthetic immune organoids. ACS Central Sci. 2023;9(4):787\u2013804.","journal-title":"ACS Central Sci"},{"issue":"104","key":"570_CR173","doi-asserted-by":"publisher","first-page":"eadp 6667","DOI":"10.1126\/sciimmunol.adp6667","volume":"10","author":"R Lutz","year":"2025","unstructured":"Lutz R, et al. Bone marrow breakout lesions act as key sites for tumor-immune cell diversification in multiple myeloma. Sci Immunol. 2025;10(104):eadp6667.","journal-title":"Sci Immunol"},{"issue":"11","key":"570_CR174","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1002\/jbmr.4171","volume":"35","author":"J Chen","year":"2020","unstructured":"Chen J, et al. Bone vasculature and bone marrow vascular niches in health and disease. J Bone Min Res. 2020;35(11):2103\u201320.","journal-title":"J Bone Min Res"},{"issue":"6","key":"570_CR175","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1038\/s41375-019-0674-7","volume":"34","author":"D Verma","year":"2020","unstructured":"Verma D, et al. Bone marrow niche-derived extracellular matrix-degrading enzymes influence the progression of B-cell acute lymphoblastic leukemia. Leukemia. 2020;34(6):1540\u201352.","journal-title":"Leukemia"},{"issue":"11","key":"570_CR176","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1038\/leu.2017.102","volume":"31","author":"SV Glavey","year":"2017","unstructured":"Glavey SV, et al. Proteomic characterization of human multiple myeloma bone marrow extracellular matrix. Leukemia. 2017;31(11):2426\u201334.","journal-title":"Leukemia"},{"key":"570_CR177","doi-asserted-by":"publisher","first-page":"100787","DOI":"10.1016\/j.drup.2021.100787","volume":"59","author":"J Kopecka","year":"2021","unstructured":"Kopecka J, et al. Hypoxia as a driver of resistance to immunotherapy. Drug Resist Updat. 2021;59:100787.","journal-title":"Drug Resist Updat"},{"key":"570_CR178","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.biomaterials.2016.09.003","volume":"110","author":"YS Zhang","year":"2016","unstructured":"Zhang YS, et al. Bioprinting 3D microfibrous scaffolds for engineering endothelialized myocardium and heart-on-a-chip. Biomaterials. 2016;110:45\u201359.","journal-title":"Biomaterials"},{"issue":"47","key":"570_CR179","doi-asserted-by":"publisher","first-page":"e2413684121","DOI":"10.1073\/pnas.2413684121","volume":"121","author":"N Jiang","year":"2024","unstructured":"Jiang N, et al. A closed-loop modular multiorgan-on-chips platform for self-sustaining and tightly controlled oxygenation. Proc Natl Acad Sci. 2024;121(47):e2413684121.","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"570_CR180","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3390\/cancers12020449","volume":"12","author":"S Raimondo","year":"2020","unstructured":"Raimondo S, et al. Extracellular vesicle microRNAs contribute to the osteogenic inhibition of mesenchymal stem cells in multiple myeloma. Cancers. 2020;12(2):449.","journal-title":"Cancers"},{"issue":"21","key":"570_CR181","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1182\/blood.V124.21.3403.3403","volume":"124","author":"R Bam","year":"2014","unstructured":"Bam R, et al. Sustained growth of primary myeloma cells in coculture with whole donor bone marrow is associated with induced secretion of the microenvironmental mediator of cytokinesis, hemicentin-1. Blood. 2014;124(21):3403\u20133403.","journal-title":"Blood"},{"key":"570_CR182","doi-asserted-by":"publisher","first-page":"103138","DOI":"10.1016\/j.scr.2023.103138","volume":"71","author":"N Thongsin","year":"2023","unstructured":"Thongsin N, Suwanpitak S, Wattanapanitch M. CRISPR-Cas9-mediated disruption of B2M and CIITA genes eliminates HLA class I and II expression in human induced pluripotent stem cells (MUSIi001-A-2). Stem Cell Res. 2023;71:103138.","journal-title":"Stem Cell Res"},{"issue":"5","key":"570_CR183","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41408-020-0320-7","volume":"10","author":"C Bonolo de Campos","year":"2020","unstructured":"Bonolo de Campos C, et al. \u201cDirect to drug\u201d screening as a precision medicine tool in multiple myeloma. Blood Cancer J. 2020;10(5):54.","journal-title":"Blood Cancer J"},{"issue":"34","key":"570_CR184","doi-asserted-by":"publisher","first-page":"56338","DOI":"10.18632\/oncotarget.17630","volume":"8","author":"MM Majumder","year":"2017","unstructured":"Majumder MM, et al. Identification of precision treatment strategies for relapsed\/refractory multiple myeloma by functional drug sensitivity testing. Oncotarget. 2017;8(34):56338\u201350.","journal-title":"Oncotarget"},{"issue":"8","key":"570_CR185","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1182\/bloodadvances.2019000122","volume":"4","author":"ZJ Walker","year":"2020","unstructured":"Walker ZJ, et al. Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression. Blood Adv. 2020;4(8):1628\u201339.","journal-title":"Blood Adv"},{"issue":"10","key":"570_CR186","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1038\/bcj.2011.42","volume":"1","author":"MS van der Veer","year":"2011","unstructured":"van der Veer MS, et al. The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. Blood Cancer J. 2011;1(10):e41.","journal-title":"Blood Cancer J"},{"issue":"10","key":"570_CR187","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/psp4.12450","volume":"8","author":"A Yin","year":"2019","unstructured":"Yin A, et al. A review of mathematical models for tumor dynamics and treatment resistance evolution of solid tumors. CPT Pharmacometrics Syst Pharmacol. 2019;8(10):720\u201337.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"12","key":"570_CR188","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1158\/0008-5472.CAN-17-0502","volume":"77","author":"A Silva","year":"2017","unstructured":"Silva A, et al. An ex vivo platform for the prediction of clinical response in multiple myeloma. Cancer Res. 2017;77(12):3336\u201351.","journal-title":"Cancer Res"},{"issue":"Supplement 1","key":"570_CR189","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1182\/blood-2023-190479","volume":"142","author":"R Renatino-Canevarolo","year":"2023","unstructured":"Renatino-Canevarolo R, et al. Ex vivo mathematical myeloma advisor (EMMA) - a clinical, molecular, and phenotypic platform to tailor personalized therapeutic strategies for multiple myeloma. Blood. 2023;142(Supplement 1):2280\u20132280.","journal-title":"Blood"},{"key":"570_CR190","doi-asserted-by":"publisher","first-page":"22498","DOI":"10.1038\/srep22498","volume":"6","author":"X Sun","year":"2016","unstructured":"Sun X, Bao J, Shao Y. Mathematical modeling of therapy-induced cancer drug resistance: connecting cancer mechanisms to population survival rates. Sci Rep. 2016;6:22498.","journal-title":"Sci Rep"},{"issue":"2","key":"570_CR191","doi-asserted-by":"publisher","first-page":"e70021","DOI":"10.1002\/eng2.70021","volume":"7","author":"FO Ochieng","year":"2025","unstructured":"Ochieng FO. Mathematical modeling of cancerous tumor evolution incorporating drug resistance. Eng Rep. 2025;7(2):e70021.","journal-title":"Eng Rep"},{"issue":"12","key":"570_CR192","doi-asserted-by":"publisher","first-page":"e005360","DOI":"10.1136\/jitc-2022-005360","volume":"10","author":"L Liu","year":"2022","unstructured":"Liu L, et al. Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse. J Immunother Cancer. 2022;10(12):e005360.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"570_CR193","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/s42003-025-08137-1","volume":"8","author":"L Koenig","year":"2025","unstructured":"Koenig L, et al. A microfluidic bone marrow chip for the safety profiling of biologics in pre-clinical drug development. Commun Biol. 2025;8(1):754.","journal-title":"Commun Biol"}],"container-title":["Journal of Biological Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13036-025-00570-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13036-025-00570-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13036-025-00570-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T12:03:42Z","timestamp":1762257822000},"score":1,"resource":{"primary":{"URL":"https:\/\/jbioleng.biomedcentral.com\/articles\/10.1186\/s13036-025-00570-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":193,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["570"],"URL":"https:\/\/doi.org\/10.1186\/s13036-025-00570-4","relation":{},"ISSN":["1754-1611"],"issn-type":[{"value":"1754-1611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"98"}}